Left Atrial Appendage

Among patients with nonvalvular atrial fibrillation, left atrial appendage closure with a second‐generation device was associated with high success rates and a low risk for procedure‐related adverse events, researchers reported.

Acutus Medical announced the FDA clearance and commercial launch of its new left-heart access system for use with the Boston Scientific’s left atrial appendage closure device.

After left atrial appendage occlusion with a next-generation device, patients with atrial fibrillation had similar outcomes at 45 days regardless of medication regimen, researchers reported at TVT: The Structural Heart Summit.

Patients who underwent left atrial appendage closure with a next-generation device were significantly less likely to experience in-hospital major adverse events, including pericardial effusion, compared with an earlier-generation device.

A next-generation left atrial appendage closure device conferred low rates of adverse events and peri-device leak in a real-world cohort at 45 days, according to results of the SURPASS study.

LAA closure (Amplatzer Amulet, Abbott, or Watchman, Boston Scientific) or non-vitamin K antagonist oral anticoagulants in patients with AF.

This year, Transcatheter Cardiovascular Therapeutics was held as a hybrid meeting Nov. 4 to 6, with some participants attending in person in Orlando and others attending virtually.

Head-to-head comparison of two LAA closure devices (Amplatzer Amulet, Abbott, and Watchman FLX or 2.5, Boston Scientific).

The Lariat left atrial appendage ligation device was safe and successful at excluding the left atrial appendage in patients with persistent atrial fibrillation, researchers reported at the American Heart Association Scientific Sessions.

Healio and Cardiology Today have curated a list of the most-read headlines from TCT 2021.